Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib with or without Obinutuzumab in Early-Stage CLL/SLL
NCT03516617Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2018
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Mayo Clinic. Started Sep 2018; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03516617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516617.